Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

33.00

Mkt cap

1.9B

Volume

328K

High

33.18

P/E Ratio

15.56

52-wk high

41.61

Low

32.42

Div yield

N/A

52-wk low

27.14

Needham analyst Ami Fadia maintains a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) but has lowered the price target from $66 to $53.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 10:04 am

Raymond James analyst Danielle Brill has maintained an Outperform rating on Harmony Biosciences (NASDAQ:HRMY), but lowered the price target from $58 to $26.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:21 am

US stocks traded lower with the Nasdaq Composite falling more than 1%. Wells Fargo reported better-than-expected earnings for Q3, with EPS reaching $1.48, beating the consensus of $1.24 and $0.86 a year ago. The bank reported Q3 revenues of $20.86 billion, up 21% Y/Y, above the consensus of $20.11 billion. Sigma Additive Solutions, Comtech Telecommunications, and SunOpta saw their shares rise after positive news. Outset Medical, SMART Global Holdings, and Harmony Biosciences Holdings saw their shares drop after negative news.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 6:50 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. Bio-Path Hldgs, Processa Pharma, Harpoon Therapeutics, SELLAS Life Sciences Gr, Agape ATP, and Assure Hldgs saw their stocks rise, with Bio-Path Hldgs leading the gainers with a 60.6% increase. On the other hand, Bellerophon Therapeutics, Outset Medical, Harmony Biosciences, Comera Life Sciences, Catalyst Biosciences, and PMV Pharma saw their stocks decline, with Bellerophon Therapeutics leading the losers with a 64.9% decrease.

Portfolio Pulse from Benzinga Insights

October 13, 2023 | 5:31 pm

The article lists the stocks that gained and lost the most during Friday's mid-day trading session. Among the gainers were Sigma Additive Solutions, Bio-Path Holdings, and Shift Technologies, while the losers included Bellerophon Therapeutics, Outset Medical, and MSP Recovery. The article also mentions several companies that reported better-than-expected earnings, such as Comtech Telecommunications and JPMorgan Chase, and others that lowered their guidance or reported worse-than-expected results, such as Belden and SMART Global Holdings.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 5:14 pm

US stocks traded lower with the Nasdaq Composite falling over 1% on Friday. Energy shares climbed by 1.7% while information technology shares rose by just 0.1%. Citigroup Inc reported a 9% YoY increase in net revenue to $20.14 billion, beating the consensus of $19.32 billion. Sigma Additive Solutions, Comtech Telecommunications, and SunOpta saw their shares rise after positive news. Outset Medical, SMART Global Holdings, and Harmony Biosciences Holdings saw their shares drop due to negative news.

Portfolio Pulse from Lisa Levin

October 13, 2023 | 4:02 pm

Harmony Biosciences Holdings Inc (NASDAQ:HRMY) announced topline results from the INTUNE Phase 3 study of pitolisant in patients with idiopathic hypersomnia (IH). Approximately 83% of patients responded positively to the treatment, however, no statistically significant difference was observed between pitolisant and placebo groups on the primary endpoint. The safety profile of pitolisant was consistent with previous findings. HRMY shares are down 36.20% at $19.30.

Portfolio Pulse from Vandana Singh

October 13, 2023 | 2:23 pm

Harmony Biosciences reported no statistically significant difference between pitolisant and placebo in its Phase 3 INTUNE study for IH. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:10 pm

Harmony Biosciences has released topline results from the INTUNE Phase 3 study of pitolisant for idiopathic hypersomnia. The study found no statistically significant difference between pitolisant and placebo groups on the Epworth Sleepiness Scale, which was the primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

October 13, 2023 | 12:06 pm

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has completed its acquisition of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) for $60 million. The deal includes potential additional payments of up to $140 million subject to the achievement of specific milestones. Zynerba is known for its pharmaceutically produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. Its lead candidate, Zygel, could serve 80,000 U.S. patients diagnosed with Fragile X syndrome and another 80,000 diagnosed with 22q deletion syndrome.

Portfolio Pulse from Jelena Martinovic

October 11, 2023 | 1:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.